Scientists Report RegeneRx's TB4 Decreases Inflammation And Restores Corneal Clarity After Eye Injury.

BETHESDA, Md. -- RegeneRx Biopharmaceuticals, Inc. (AMEX:RGN) (www.regenerx.com) reported today that a paper published by Dr. Gabriel Sosne, Assistant Professor of Ophthalmology at Wayne State University and the Kresge Eye Institute in Detroit, Michigan, and his colleagues, in the journal Investigative Ophthalmology and Visual Science (2005 Jul;46(7):2388-95), has shown in laboratory animals that thymosin beta 4 (TB4) treatment decreases corneal inflammation thereby promoting corneal wound repair and restoring clarity after an eye injury.

"We have begun to describe TB4's ability to modulate MMP-9 levels in the cornea and that is significant because MMP-9 overexpression is often associated with dysregulated inflammation and impaired healing. TB4 treatment restores the clarity of the cornea in our model of injury and these findings translate into the potential for improved visual acuity," according to Dr. Sosne. "This new data continues to support the use of TB4 to treat eye wounds and we look forward to testing this compound in the clinic."

RegeneRx Biopharmaceuticals, Inc.

RegeneRx (www.regenerx.com) is a biopharmaceutical company developing TB4 as a platform technology for the treatment of acute and chronic wounds and for a variety of human diseases involving tissue and organ repair under an exclusive world-wide license from the National Institutes of Health. The company holds over fifty world-wide patents and patent applications related to dermal, ocular, and internal wounds and tissue repair, including the treatment and prevention of cardiac and neurological injuries, as well as issued patents related to the treatment of septic shock. RegeneRx recently received clearance from the U.S. FDA for its first three Phase II dermal wound healing clinical trials and has targeted cardiac and ophthalmic wound healing as part of its ongoing clinical development program.

The information in this press release may include certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements concern the Company's current expectations regarding future events, including the regulatory approval process and the ongoing and prospective development and commercialization of Ta4 and possible future benefits to the Company, its stockholders, and patients. Due to the nature of clinical trials, product development and the regulatory approval process, the forward-looking statements contained in this press release are subject to risks and uncertainties, including those reflected in the Company's filings with the Securities and Exchange Commission, particularly its most recent Annual Report on Form 10-KSB. The Company assumes no obligation to update or revise any forward-looking statements made herein or any other forward-looking statements made by the Company.